Diogo D.G. Bugano , Neda Kalhor , Jianjun Zhang , Michele Neskey , William N. William Jr
{"title":"接受厄洛替尼治疗的肺腺癌患者的鳞状细胞转化:与T790M突变共存","authors":"Diogo D.G. Bugano , Neda Kalhor , Jianjun Zhang , Michele Neskey , William N. William Jr","doi":"10.1016/j.ctrc.2015.03.007","DOIUrl":null,"url":null,"abstract":"<div><p>We report on a patient with metastatic lung adenocarcinoma who underwent testing for EGFR mutations in a pleural effusion that failed to show any alterations and received standard first and second-line chemotherapy. She received erlotinib as third-line therapy with a prolonged partial response. At time of progression, re-biopsy showed squamous cell carcinoma, supported by histology and immunohistochemistry. Molecular profiling confirmed EGFR exon 21 L858R and exon 20 T790M mutations. Squamous cell transformation should not defer EGFR re-sequencing.</p></div>","PeriodicalId":90461,"journal":{"name":"Cancer treatment communications","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ctrc.2015.03.007","citationCount":"13","resultStr":"{\"title\":\"Squamous-cell transformation in a patient with lung adenocarcinoma receiving erlotinib: Co-occurrence with T790M mutation\",\"authors\":\"Diogo D.G. Bugano , Neda Kalhor , Jianjun Zhang , Michele Neskey , William N. William Jr\",\"doi\":\"10.1016/j.ctrc.2015.03.007\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>We report on a patient with metastatic lung adenocarcinoma who underwent testing for EGFR mutations in a pleural effusion that failed to show any alterations and received standard first and second-line chemotherapy. She received erlotinib as third-line therapy with a prolonged partial response. At time of progression, re-biopsy showed squamous cell carcinoma, supported by histology and immunohistochemistry. Molecular profiling confirmed EGFR exon 21 L858R and exon 20 T790M mutations. Squamous cell transformation should not defer EGFR re-sequencing.</p></div>\",\"PeriodicalId\":90461,\"journal\":{\"name\":\"Cancer treatment communications\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.ctrc.2015.03.007\",\"citationCount\":\"13\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer treatment communications\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2213089615000146\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer treatment communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213089615000146","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Squamous-cell transformation in a patient with lung adenocarcinoma receiving erlotinib: Co-occurrence with T790M mutation
We report on a patient with metastatic lung adenocarcinoma who underwent testing for EGFR mutations in a pleural effusion that failed to show any alterations and received standard first and second-line chemotherapy. She received erlotinib as third-line therapy with a prolonged partial response. At time of progression, re-biopsy showed squamous cell carcinoma, supported by histology and immunohistochemistry. Molecular profiling confirmed EGFR exon 21 L858R and exon 20 T790M mutations. Squamous cell transformation should not defer EGFR re-sequencing.